Anzeige
Meldung des Tages: „Echte Revolution“: Dieses MedTech-Unternehmen greift nach dem Milliardenmarkt

TransCode Therapeutics Inc News

Aktie
WKN:  A40VJX ISIN:  US89357L4023
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

TransCode Therapeutics Inc News

08.05.25 - PR Newswire
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported PR Newswire
05.05.25 - PR Newswire
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split PR Newswire
02.05.25 - PR Newswire
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split PR Newswire
01.05.25 - PR Newswire
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer PR Newswire
21.04.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting PR Newswire
27.03.25 - PR Newswire
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 PR Newswire
25.03.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering PR Newswire
23.03.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
13.03.25 - PR Newswire
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial PR Newswire
25.02.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire
06.02.25 - PR Newswire
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial PR Newswire
04.02.25 - PR Newswire
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting PR Newswire
14.01.25 - PR Newswire
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial PR Newswire
07.01.25 - PR Newswire
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements PR Newswire

Newssuche

Videos

newspaper
16.12.25 +1,32%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Kein Weihnachtswunder
DiagnosTear Technologies Inc
0,352 €
-3,83%
DiagnosTear Technologies Inc Chart
Blutuntersuchung ohne Blutabnahme!
Mehr zur Aktie »